Articles dans des revues avec comité de lecture (55)
  1. 10. Casas, A. I., Nogales, C., Mucke, H. H., Petraina, A., Cuadrado, A., Rojo, A. A., Ghezzi,, Jaquet, V., Augsburger, F., Dufrasne, F., Soubhye, J., Deshwal, S., Di Sante, M., Kaludercic, N., Di Lisa, F., & Schmidt, H. A. E. (2020). On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacological reviews, 72(4), 801-828. doi:10.1124/pr.120.019422
  2. 11. Soubhye, J., Van Antwerpen, P., & Dufrasne, F. (2018). Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents. Current medicinal chemistry. doi:10.2174/0929867325666180117103919
  3. 12. Rens, C., Laval, F., Wattiez, R., Lefèvre, P., Dufrasne, F., Daffé, M., & Fontaine, V. (2018). I3-Ag85 effect on phthiodiolone dimycocerosate synthesis. Tuberculosis, 108, 93-95. doi:10.1016/j.tube.2017.10.007
  4. 13. Frederick, R., Pochet, L., de Tullio, P., & Dufrasne, F. (2017). 31ièmes Journées franco-belges de pharmacochimie: Meeting report. Pharmaceuticals, 10(4), 94. doi:10.3390/ph10040094
  5. 14. Soubhye, J., Chikh Alard, I., Aldib, I., Prévost, M., Gelbcke, M., De Carvalho, A., Furtmüller, P. G., Obinger, C., Flemmig, J., Tadrent, S., Meyer, F., Rousseau, A., Neve, J., Mathieu, V., Zouaoui Boudjeltia, K., Dufrasne, F., & Van Antwerpen, P. (2017). Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure. Journal of medicinal chemistry, 60(15), 6563-6586. doi:10.1021/acs.jmedchem.7b00285
  6. 15. Soubhye, J., Gelbcke, M., Van Antwerpen, P., Dufrasne, F., Boufadi, Y. M., Neve, J., Furtmüller, P. G., Obinger, C., Zouaoui Boudjeltia, K., & Meyer, F. (2017). From Dynamic Combinatorial Chemistry to in Vivo Evaluation of Reversible and Irreversible Myeloperoxidase Inhibitors. ACS Medicinal Chemistry Letters, 8(2), 206-210. doi:10.1021/acsmedchemlett.6b00417
  7. 16. Marloye, M., Berger, G., Gelbcke, M., & Dufrasne, F. (2016). A survey of the mechanisms of action of anticancer transition metal complexes. Future Medicinal Chemistry, 8(18), 2263-2286. doi:10.4155/fmc-2016-0153
  8. 17. Soubhye, J., Meyer, F., Furtmüller, P. G., Obinger, C., Dufrasne, F., & Van Antwerpen, P. (2016). Characterization of chemical features of potent myeloperoxidase inhibitors. Future Medicinal Chemistry, 8(11), 1163-1177. doi:10.4155/fmc-2016-0031
  9. 18. Aldib, I., Gelbcke, M., Soubhye, J., Prévost, M., Furtmüller, P. G., Obinger, C., Elfving, B., Chikh Alard, I., Roos, G., Delporte, C., Berger, G., Dufour, D., Zouaoui Boudjeltia, K., Neve, J., Dufrasne, F., & Van Antwerpen, P. (2016). Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study. European journal of medicinal chemistry, 123, 746-762. doi:10.1016/j.ejmech.2016.07.053
  10. 19. Soubhye, J., Aldib, I., Delporte, C., Prévost, M., Dufrasne, F., & Van Antwerpen, P. (2016). Myeloperoxidase as a Target for Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors. Current medicinal chemistry. doi:10.2174/0929867323666160607111806
  11. 20. Sá, J., Czapla-Masztafiak, J., Lipiec, E., Kayser, Y., Fernandes, D. L. A., Szlachetko, J., Dufrasne, F., & Berger, G. (2016). Resonant X-ray emission spectroscopy of platinum(ii) anticancer complexes. Analyst, 141(4), 1226-1232. doi:10.1039/c5an02490k
  12. 21. Frederick, R., Pochet, L., de Tullio, P., & Dufrasne, F. (2015). 29ièmes journées Franco-Belges de Pharmacochimie: Meeting report. Pharmaceuticals, 8(4), 758-777. doi:10.3390/ph8040758
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 Suivant >>